Efficacy and safety of sodium phosphate for colon cleansing in type 2 diabetes mellitus.
OBJECTIVE
The need for colonoscopy is common among diabetic patients. However, there are no standards per se for bowel preparation in patients with type 2 diabetes. In this study, we evaluated the efficacy, safety, and tolerability of sodium phosphate (NaP), and the quality of bowel cleansing in relation to glycemic control and late complications.


METHODS
A total of 50 consecutive type 2 diabetic patients and 50 non-diabetic patients underwent bowel preparation by NaP. Fasting blood glucose, sodium (Na), potassium (K), calcium (Ca), phosphorus (P), magnesium, and creatinine levels were measured on the procedure day. Patients were given a tolerability questionnaire regarding symptoms.


RESULTS
With regard to bowel preparation quality, optimal bowel cleansing was achieved in 35 (70%) diabetic and 47 (94%) non-diabetic patients (P = 0.002). Abdominal pain or discomfort during and an hour after the procedure was similar in both groups (P >0.05). The changes in Na, K, Ca, P and creatinine levels after NaP use did not reach statistical significance between the groups (P >0.05). In the diabetic patients, there was a significant correlation between the quality of bowel cleansing and mean age, duration of diabetes mellitus, level of hemoglobin A1c (HbA1c), fasting blood glucose level, and diabetic late complications (P <0.05).


CONCLUSIONS
These data suggest that NaP is safe and tolerable in diabetic patients, but the quality of bowel cleansing is worse than in non-diabetic patients. These observations support the concept that the quality of bowel cleansing in those with type 2 diabetes is closely related to the duration and regulation of the disease and the presence of late complications.
Ozturk
Nevin Akcaer
NA
Department of Gastroenterology, Faculty of Medicine, Baskent University, Konya, Turkey.
Gokturk
Huseyin Savas
HS
Demir
Mehmet
M
Unler
Gulhan Kanat
GK
Gur
Gurden
G
Yilmaz
Ugur
U
D002400:Cathartics / Q000009:adverse effects / Q000494:pharmacology*; D003113:Colonoscopy; D003924:Diabetes Mellitus, Type 2; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D006442:Glycated Hemoglobin / Q000187:drug effects; D006801:Humans; D008297:Male; D016555:Matched-Pair Analysis; D008875:Middle Aged; D010710:Phosphates / Q000009:adverse effects / Q000494:pharmacology*
D002400:Cathartics; D006442:Glycated Hemoglobin; D010710:Phosphates; C018279:sodium phosphate